Theriva Biologics (TOVX) Insider Trading & Ownership $1.08 -0.11 (-8.90%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock Theriva Biologics (NYSEAMERICAN:TOVX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.05%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$106,380.00Number OfInsiders Selling(Last 3 Years)0 Get TOVX Insider Trade Alerts Want to know when executives and insiders are buying or selling Theriva Biologics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TOVX Insider Buying and Selling by Quarter Remove Ads Theriva Biologics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/6/2023Steven A ShallcrossCEOBuy1,040$15.75$16,380.00 2/10/2023Steven A ShallcrossCEOBuy1,000$26.00$26,000.00 2/2/2023Steven A ShallcrossCEOBuy1,000$23.50$23,500.00 1/25/2023Steven A ShallcrossCEOBuy1,000$21.75$21,750.00 1/20/2023Steven A ShallcrossCEOBuy1,000$18.75$18,750.00 (Data available from 1/1/2013 forward) TOVX Insider Trading Activity - Frequently Asked Questions Who is on Theriva Biologics's Insider Roster? The list of insiders at Theriva Biologics includes Steven A Shallcross. Learn more on insiders at TOVX. What percentage of Theriva Biologics stock is owned by insiders? 3.05% of Theriva Biologics stock is owned by insiders. Learn more on TOVX's insider holdings. Which Theriva Biologics insiders have been buying company stock? The following insider purchased TOVX shares in the last 24 months: Steven A Shallcross ($16,380.00). How much insider buying is happening at Theriva Biologics? Insiders have purchased a total of 1,040 TOVX shares in the last 24 months for a total of $16,380.00 bought. Theriva Biologics Key ExecutivesMr. Steven A. Shallcross CPA (Age 63)CEO, CFO, Treasurer, Corporate Secretary & Director Compensation: $993.46kDr. Vince Wacher Ph.D.Head of Product & Corporate DevelopmentDr. Michael Kaleko M.D.Ph.D., Senior Vice President of Research & DevelopmentDr. Ramon Alemany Ph.D.Senior VP of Discovery & Chairman of Scientific Advisory Board More Insider Trading Tools from MarketBeat Related Companies MRKR Insider Trades FLGC Insider Trades ORGS Insider Trades BGXX Insider Trades TXMD Insider Trades SPRB Insider Trades NERV Insider Trades APRE Insider Trades ATHA Insider Trades BMRA Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Casey’s General Stores Insider Buys Shares of This Must-Own StockNVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish This page (NYSEAMERICAN:TOVX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
